Suyun Ji

Suyun Ji

Auto-generated profile, based on publicly available information

Suyun Ji

Department of Dermatology Dermatology Hospital, Southern Medical University Guangzhou China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
ZHZhanying Hou
Zhanying Hou
XSXuehan Su
Xuehan Su
GHGuangming Han
Guangming Han
RXRuzeng Xue
Ruzeng Xue
YCYangxia Chen
Yangxia Chen
SJSuyun Ji
Suyun Ji
Background: Systemic sclerosis (SSc) is a rare disabling connective tissue disease with few available treatment options. Diffuse cutaneous systemic sclerosis (dcSSc) is associated with high mortality. A previous experiment has shown that JAK2 inhibitor can significantly improve skin fibrosis in bleomycin (BLM)-induced murine model, including reducing dermal thickening and collagen accumulation. We aimed to describe the efficacy of oral JAK1/2 inhibitor baricitinib in SSc patients, especially focusing on skin fibrosis and microvascular manifestations.Methods: We described the different effects of oral selective JAK1, JAK2, or JAK3 inhibitor treatment in a BLM-induced skin fibrosis mouse model. Furthermore, 10 adult patients with dcSSc were treated with baricitinib. We assessed the changes in modified rodman skin score (mRSS) and digital ulcer net burden at week 12 and 24 from baseline. We also compared the absolute changes in scores on the Scleroderma Health Assessment Questionnaire (SHAQ) and a total score on the St. George's Respiratory Questionnaire (SGRQ) over a 24-week period.Results: In the experimental mouse model of skin fibrosis, a JAK1 and JAK2 inhibitor ameliorated skin fibrosis, and a JAK2 inhibitor had the most obvious effect. Treatment with the JAK2 inhibitor also blunted the capillary rarefaction. We demonstrated that skin fibrosis and digital ulcers were significantly relieved in 10 SSc patients treated with baricitinib. The mRSS significantly improved at week 12 from baseline, with a mean change in mRSS of −8.3 [95% confidence interval (CI), −12.03 to −4.574; p = 0.0007] and improved greater at week 24 to −11.67 (95% CI, −16.84 to −6.496; p = 0.0008). Among the four patients with digital ulcers (DU), three were completely healed at week 24, the number of ulcers in another patient was significantly reduced, and there was no patient with new ulcers. Only one adverse event (AE) of herpes zoster was observed.Conclusions: Our results indicate that selective JAK1 and JAK2 inhibitor alleviates skin fibrosis, and oral JAK1/2 inhibitor baricitinib is a potentially effective treatment for dcSSc patients with skin fibrosis and DU. Baricitinib was well-tolerated by most patients in this study. Additional large clinical trials are needed to confirm our pilot findings.Chinese Clinical Trial Registry Number: ChiCTR2000030995.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HXHui Xiong
Hui Xiong
ZGZhixuan Guo
Zhixuan Guo
ZTZengqi Tang
Zengqi Tang
XAXuechen Ai
Xuechen Ai
QQQing Qi
Qing Qi
QGQing Guo
Qing Guo
The defective MEK/ERK signaling pathway and downstream hypomethylation pattern of lymphocytes are crucial for the pathogenesis of systemic lupus erythematosus (SLE). However, the role that the mesenchymal stem cells play in the MEK/ERK signaling pathway and DNA methylation of peripheral blood mononuclear cells (PBMC) from SLE patients remains unknown. In this study, we found that the MEK/ERK signaling pathway of PBMC from SLE patients was activated after the coculture with bone marrow‐derived mesenchymal stem cells (BM‐MSC) compared with that from the control group. In addition, the expression level of DNA methyltransferase 1 (DNMT1) increased while the levels of CD70, integrin, alpha L (ITGAL), selectin‐l, and IL‐13 were reduced in PBMC from SLE patients. However, no obvious effect of BM‐MSC on PBMC from healthy controls was observed. These findings revealed that BM‐MSC might downregulate the expression of methylation‐sensitive genes and then suppress the autoactivated PBMC via the MEK/ERK signaling pathway. And it may be one of the mechanisms that BM‐MSC ameliorated SLE.

5 January 2023 in Frontiers in Medicine
Verified
Journal Article
Open access
ZHZhanying Hou
Zhanying Hou
XSXuehan Su
Xuehan Su
GHGuangming Han
Guangming Han
RXRuzeng Xue
Ruzeng Xue
YCYangxia Chen
Yangxia Chen
SJSuyun Ji
Suyun Ji
Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis

10 March 2026 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
WJWenjing Jiang
Wenjing Jiang
XXXinyang Xie
Xinyang Xie
SYSai Yang
Sai Yang
RXRui Xu
Rui Xu
JCJui-Wen Chang
Jui-Wen Chang
FWFang Wang
Fang Wang

22 July 2026 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
SLShiqi Ling
Shiqi Ling
SJSuyun Ji
Suyun Ji
ZZZhe Zhuang
Zhe Zhuang
JGJinglin Gao
Jinglin Gao
YZYongjie Zeng
Yongjie Zeng
GZGuannan Zhu
Guannan Zhu